Morgan Stanley’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Morgan Stanley’s Portfolio NEXI Stock Details NEXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-34	Closed	-$76	–	8019
2023 Q4	$76	Buy	34 +16	+89%	+$54	﹤0.01%	7548
2023 Q3	$94	Buy	+18	New	+$112	﹤0.01%	7447
2023 Q1	–	Sell	-33	Closed	-$199	–	7862
2022 Q4	$199	Sell	33 -104	-76%	-$1.3K	﹤0.01%	7645
2022 Q3	$2K	Sell	137 -533	-80%	-$15.6K	﹤0.01%	7502
2022 Q2	$27K	Buy	670 +516	+335%	+$31.9K	﹤0.01%	6878
2022 Q1	$16K	Sell	154 -1,354	-90%	-$99.4K	﹤0.01%	7246
2021 Q4	$174K	Buy	1,508 +1,415	+1,522%	+$340K	﹤0.01%	6139
2021 Q3	$35K	Sell	93 -1,092	-92%	-$366K	﹤0.01%	6875
2021 Q2	$484K	Buy	1,185 +153	+15%	+$70.5K	﹤0.01%	5540
2021 Q1	$493K	Buy	+1,032	New	+$562K	﹤0.01%	5158

Other funds holding NEXI

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley's NEXI Position: Q1 2024 in Review

Morgan Stanley sold out of NexImmune, Inc. Common Stock (NEXI) in Q1 2024, closing a stake of 34 shares — an estimated $76 sold.

Morgan Stanley first reported a position in NEXI in Q1 2021 and held it in 10 quarters. The position peaked at $493K in Q1 2021. 12 funds tracked by Wall St. Rank hold NEXI as of Q1 2024.

Morgan Stanley reported no remaining NexImmune, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Morgan Stanley sold 34 NexImmune, Inc. Common Stock shares in Q1 2024, an estimated $76.
Morgan Stanley first reported a position in NexImmune, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Morgan Stanley's NexImmune, Inc. Common Stock position peaked at $493K in Q1 2021.
12 funds tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.